Regentis Biomaterials Ltd. Ordinary Shares
Key Metrics
Market Snapshot
About
Regentis Biomaterials Ltd. Ordinary Shares (RGNT) is a regenerative medicine company based in Herzliya, Israel. Incorporated in 2004, the company develops and commercializes tissue repair solutions, with its activities directed at the United States market. Its focus is on technologies intended to support the treatment and regeneration of damaged or diseased tissue.
The company's work is built around its Gelrin platform. Gelrin is based on a hydrogel matrix made from polyethylene glycol diacrylate and denatured fibrinogen, and it is designed to aid in the repair and regeneration of tissue. Building on this platform, the company offers GelrinC, a cell-free and off-the-shelf hydrogel product. GelrinC has been studied in a Phase II clinical trial for the treatment of cartilage injuries in the knee, reflecting a focus on orthopedic tissue repair.
As a regenerative medicine company, Regentis Biomaterials concentrates on developing biomaterial-based treatments rather than traditional drugs, and on advancing those treatments through the clinical stages required for medical products. The cell-free and off-the-shelf nature of GelrinC points to an approach intended to be ready for use without the need to harvest or culture a patient's own cells in advance. By centering its efforts on hydrogel technology for cartilage and tissue repair, RGNT positions itself within the field of regenerative therapies for musculoskeletal injuries. The source describes the company's platform and clinical focus but does not provide financial details, so this overview reflects the products and development activities that have been disclosed.